BBOT shakes up leadership as RAS competitors get more visibility

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as

New leadership team takes shape at BridgeBio Oncology (Nasdaq: BBOT)

Experimental cancer drug drove tumor regressions in KRAS preclinical models

BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma